The origins of cancer robustness and evolvability.

Unless diagnosed early, many adult cancers remain incurable diseases. This is despite an intense global research effort to develop effective anticancer therapies, calling into question the use of rational drug design strategies in targeting complex disease states such as cancer. A fundamental challenge facing researchers and clinicians is that cancers are inherently robust biological systems, able to survive, adapt and proliferate despite the perturbations resulting from anticancer drugs. It is essential that the mechanisms underlying tumor robustness be formally studied and characterized, as without a thorough understanding of the principles of tumor robustness, strategies to overcome therapy resistance are unlikely to be found. Degeneracy describes the ability of structurally distinct system components (e.g. proteins, pathways, cells, organisms) to be conditionally interchangeable in their contribution to system traits and it has been broadly implicated in the robustness and evolvability of complex biological systems. Here we focus on one of the most important mechanisms underpinning tumor robustness and degeneracy, the cellular heterogeneity that is the hallmark of most solid tumors. Based on a combination of computational, experimental and clinical studies we argue that stochastic noise is an underlying cause of tumor heterogeneity and particularly degeneracy. Drawing from a number of recent data sets, we propose an integrative model for the evolution of therapy resistance, and discuss recent computational studies that propose new therapeutic strategies aimed at defeating the adaptable cancer phenotype.

[1]  M. Tomasson Cancer stem cells: A guide for skeptics , 2009, Journal of cellular biochemistry.

[2]  Kentaro Yamashita,et al.  Global DNA demethylation in gastrointestinal cancer is age dependent and precedes genomic damage. , 2006, Cancer cell.

[3]  M. Freeman Feedback control of intercellular signalling in development , 2000, Nature.

[4]  C. Croce,et al.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[5]  W. Stolz,et al.  Deficiency of a novel retinoblastoma binding protein 2-homolog is a consistent feature of sporadic human melanoma skin cancer. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[6]  R. Day,et al.  Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy. , 1986, Cancer research.

[7]  H. Lyng,et al.  Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis , 2000, British Journal of Cancer.

[8]  Larry S Yaeger,et al.  How evolution guides complexity , 2009, HFSP journal.

[9]  Ryan D. Morin,et al.  Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution , 2009, Nature.

[10]  H. Kitano Cancer as a robust system: implications for anticancer therapy , 2004, Nature Reviews Cancer.

[11]  P. Glazer,et al.  Regulation of DNA repair in hypoxic cancer cells , 2007, Cancer and Metastasis Reviews.

[12]  A. Shilatifard,et al.  An operational definition of epigenetics. , 2009, Genes & development.

[13]  K. Kinzler,et al.  Genetic instabilities in human cancers , 1998, Nature.

[14]  Claude Preudhomme,et al.  Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment. , 2003, Seminars in hematology.

[15]  H. Heng,et al.  Genome based cell population heterogeneity promotes tumorigenicity: The evolutionary mechanism of cancer , 2009, Journal of cellular physiology.

[16]  B. Tran,et al.  Survival comparison between glioblastoma multiforme and other incurable cancers , 2010, Journal of Clinical Neuroscience.

[17]  R. Hill,et al.  The tumor microenvironment and metastatic disease , 2008, Clinical & Experimental Metastasis.

[18]  D. Schluter,et al.  Adaptation from standing genetic variation. , 2008, Trends in ecology & evolution.

[19]  M. Landthaler,et al.  Retinoblastoma-binding protein 2-homolog 1: a retinoblastoma-binding protein downregulated in malignant melanomas , 2005, Modern Pathology.

[20]  James M. Whitacre,et al.  Degeneracy: a link between evolvability, robustness and complexity in biological systems , 2009, Theoretical Biology and Medical Modelling.

[21]  H. Hermeking p53 enters the microRNA world. , 2007, Cancer cell.

[22]  J. Melo,et al.  Primitive, Quiescent and Difficult to Kill: The Role of Non-Proliferating Stem Cells in Chronic Myeloid Leukemia , 2006, Cell cycle.

[23]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[24]  L. Loeb,et al.  Efficiency of carcinogenesis with and without a mutator mutation , 2006, Proceedings of the National Academy of Sciences.

[25]  Forest M White,et al.  Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma , 2007, Proceedings of the National Academy of Sciences.

[26]  Farren J. Isaacs,et al.  Phenotypic consequences of promoter-mediated transcriptional noise. , 2006, Molecular cell.

[27]  R. Gillies,et al.  Why do cancers have high aerobic glycolysis? , 2004, Nature Reviews Cancer.

[28]  S. Lindquist,et al.  Hsp90 Potentiates the Rapid Evolution of New Traits: Drug Resistance in Diverse Fungi , 2005, Science.

[29]  M. West-Eberhard,et al.  Developmental plasticity and the origin of species differences , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[30]  K. Rejniak,et al.  Current trends in mathematical modeling of tumor–microenvironment interactions: a survey of tools and applications , 2010, Experimental biology and medicine.

[31]  C. Swanton,et al.  Chromosomal instability: A composite phenotype that influences sensitivity to chemotherapy , 2009, Cell cycle.

[32]  D. Compton,et al.  Mechanisms of Chromosomal Instability , 2010, Current Biology.

[33]  Ben S. Wittner,et al.  A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.

[34]  P. Nowell The clonal evolution of tumor cell populations. , 1976, Science.

[35]  A. Balmain,et al.  How many mutations are required for tumorigenesis? implications from human cancer data , 1993 .

[36]  M. Meyerson,et al.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.

[37]  I. Tannock,et al.  Retreatment of patients with the same chemotherapy: implications for clinical mechanisms of drug resistance. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  G. Edelman,et al.  Degeneracy and complexity in biological systems , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Tischfield,et al.  Somatic recombination redux , 2003, Nature Genetics.

[40]  C. Schlichting Hidden Reaction Norms, Cryptic Genetic Variation, and Evolvability , 2008, Annals of the New York Academy of Sciences.

[41]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[42]  C. Roberts,et al.  Epigenetics and cancer without genomic instability , 2009, Cell cycle.

[43]  S. Leibler,et al.  Bacterial Persistence as a Phenotypic Switch , 2004, Science.

[44]  John Doyle,et al.  Evolutionary dynamics and highly optimized tolerance. , 2005, Journal of theoretical biology.

[45]  Z. Herceg,et al.  Epigenetic drivers and genetic passengers on the road to cancer. , 2008, Mutation research.

[46]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.

[47]  J. Herman,et al.  Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. , 1999, Cancer research.

[48]  M. Pigliucci,et al.  Phenotypic plasticity and evolution by genetic assimilation , 2006, Journal of Experimental Biology.

[49]  Axel Bender,et al.  Networked buffering: a basic mechanism for distributed robustness in complex adaptive systems , 2009, Theoretical Biology and Medical Modelling.

[50]  J. Crowe,et al.  Preservation of mammalian cells—learning nature's tricks , 2000, Nature Biotechnology.

[51]  S. Kauffman Homeostasis and Differentiation in Random Genetic Control Networks , 1969, Nature.

[52]  The age distribution of cancer and a multi-stage theory of carcinogenosis , 2004 .

[53]  L. Loeb,et al.  Mutational heterogeneity in human cancers: origin and consequences. , 2010, Annual review of pathology.

[54]  H. Kitano Towards a theory of biological robustness , 2007, Molecular systems biology.

[55]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[56]  Aleksandar Dakic,et al.  Tumor Growth Need Not Be Driven by Rare Cancer Stem Cells , 2007, Science.

[57]  P. Armitage,et al.  The Age Distribution of Cancer and a Multi-stage Theory of Carcinogenesis , 1954, British Journal of Cancer.

[58]  Frank J. Slack,et al.  MicroRNAs and cancer: An overview , 2008, Cell cycle.

[59]  J. Buchner,et al.  Oncogenic mutations reduce the stability of SRC kinase. , 2004, Journal of molecular biology.

[60]  Greg Gibson,et al.  Uncovering cryptic genetic variation , 2004, Nature Reviews Genetics.

[61]  O. Bogler,et al.  A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. , 1996, Cancer research.

[62]  Rafael Sanjuán,et al.  Epistasis correlates to genomic complexity , 2006, Proceedings of the National Academy of Sciences.

[63]  Kornelia Polyak,et al.  Microenvironmental regulation of cancer development. , 2008, Current opinion in genetics & development.

[64]  R. Prehn,et al.  Immunity to methylcholanthrene-induced sarcomas. , 1957, Journal of the National Cancer Institute.

[65]  L. Loeb,et al.  Errors in DNA replication as a basis of malignant changes. , 1974, Cancer research.

[66]  P. Nowell,et al.  Karyotypic evolution in human malignant melanoma. , 1986, Cancer genetics and cytogenetics.

[67]  M. Fukuoka,et al.  Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[68]  P. M. Voorhoeve,et al.  MicroRNAs: Oncogenes, tumor suppressors or master regulators of cancer heterogeneity? , 2010, Biochimica et biophysica acta.

[69]  A. Feinberg,et al.  The epigenetic progenitor origin of human cancer , 2006, Nature Reviews Genetics.

[70]  S. Lindquist,et al.  Hsp90 as a capacitor for morphological evolution , 1998, Nature.

[71]  Alexander Roesch,et al.  A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth , 2010, Cell.

[72]  Mark P Little,et al.  Cancer models, genomic instability and somatic cellular Darwinian evolution , 2010, Biology Direct.

[73]  David E. Housman,et al.  Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours , 1996, Nature.

[74]  F T Bosman,et al.  Intratumor genetic heterogeneity in advanced human colorectal adenocarcinoma , 2001, International journal of cancer.

[75]  J. Lankelma,et al.  Doxorubicin gradients in human breast cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[76]  Robert A Gatenby,et al.  A theoretical quantitative model for evolution of cancer chemotherapy resistance , 2010, Biology Direct.

[77]  K. Polyak,et al.  Tumor heterogeneity: causes and consequences. , 2010, Biochimica et biophysica acta.

[78]  A. Wagner Robustness and evolvability: a paradox resolved , 2008, Proceedings of the Royal Society B: Biological Sciences.

[79]  M. Huynen,et al.  Smoothness within ruggedness: the role of neutrality in adaptation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[80]  J. M. Murray,et al.  Optimal control for a stochastic model of cancer chemotherapy. , 2000, Mathematical biosciences.

[81]  Kornelia Polyak,et al.  Breast Tumor Heterogeneity: Cancer Stem Cells or Clonal Evolution? , 2007, Cell cycle.

[82]  Michael Landthaler,et al.  RBP2‐H1/JARID1B is a transcriptional regulator with a tumor suppressive potential in melanoma cells , 2007, International journal of cancer.

[83]  Zhong Yun,et al.  Hypoxic tumor microenvironment and cancer cell differentiation. , 2009, Current molecular medicine.

[84]  M. Landthaler,et al.  Re-expression of the retinoblastoma-binding protein 2-homolog 1 reveals tumor-suppressive functions in highly metastatic melanoma cells. , 2006, The Journal of investigative dermatology.

[85]  S. Lindquist,et al.  Heat-shock protein hsp90 governs the activity of pp60v-src kinase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[86]  David F. Horrobin,et al.  Modern biomedical research: an internally self-consistent universe with little contact with medical reality? , 2003, Nature Reviews Drug Discovery.

[87]  M. Greaves Cancer stem cells: back to Darwin? , 2010, Seminars in cancer biology.

[88]  M. Gassmann,et al.  Regulation of the multidrug resistance transporter P‐glycoprotein in multicellular tumor spheroids by hypoxia‐inducible factor‐1 and reactive oxygen species , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[89]  Rocio Sotillo,et al.  Mitotic chromosomal instability and cancer: mouse modelling of the human disease , 2010, Nature Reviews Cancer.

[90]  J. M. Nicholson,et al.  On the karyotypic origin and evolution of cancer cells. , 2009, Cancer genetics and cytogenetics.

[91]  Doyle,et al.  Highly optimized tolerance: robustness and design in complex systems , 2000, Physical review letters.

[92]  R. Beckman Mutator Mutations Enhance Tumorigenic Efficiency across Fitness Landscapes , 2009, PloS one.

[93]  J. Kuriyan,et al.  Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.

[94]  G. Wagner,et al.  Mutational robustness can facilitate adaptation , 2010, Nature.

[95]  G. Cambray,et al.  Synonymous Genes Explore Different Evolutionary Landscapes , 2008, PLoS genetics.

[96]  C. Hinshelwood,et al.  The stability of various adaptations of Bact. lactis aerogenes (Aerobacter aerogenes) , 1954, Proceedings of the Royal Society of London. Series B - Biological Sciences.

[97]  P. Turner,et al.  Robustness promotes evolvability of thermotolerance in an RNA virus , 2008, BMC Evolutionary Biology.

[98]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[99]  A. Xu,et al.  Receptor tyrosine kinase coactivation networks in cancer. , 2010, Cancer research.

[100]  A. Wagner Distributed robustness versus redundancy as causes of mutational robustness. , 2005, BioEssays : news and reviews in molecular, cellular and developmental biology.

[101]  S. Morrison,et al.  Efficient tumor formation by single human melanoma cells , 2008, Nature.

[102]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[103]  John Doyle,et al.  Complexity and robustness , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[104]  G. Parmigiani,et al.  Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers , 2008, Proceedings of the National Academy of Sciences.

[105]  K. Kinzler,et al.  Epitope landscape in breast and colorectal cancer. , 2008, Cancer research.

[106]  P. Vaupel,et al.  Hypoxia in cancer: significance and impact on clinical outcome , 2007, Cancer and Metastasis Reviews.

[107]  J. Jonkers,et al.  Modeling therapy resistance in genetically engineered mouse cancer models. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[108]  Jesse J Salk,et al.  Optimization of DNA polymerase mutation rates during bacterial evolution , 2009, Proceedings of the National Academy of Sciences.

[109]  D. Alberts,et al.  Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. , 1986, Cancer research.

[110]  Andreas Wagner,et al.  Robustness Can Evolve Gradually in Complex Regulatory Gene Networks with Varying Topology , 2007, PLoS Comput. Biol..

[111]  R. Milo,et al.  Dynamic Proteomics of Individual Cancer Cells in Response to a Drug , 2008, Science.

[112]  Carissa A. Sanchez,et al.  Evolution of neoplastic cell lineages in Barrett oesophagus , 1999, Nature Genetics.

[113]  Izhak Haviv,et al.  Co-evolution of tumor cells and their microenvironment. , 2009, Trends in genetics : TIG.

[114]  F. Arnold,et al.  Protein stability promotes evolvability. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[115]  R. Jaenisch,et al.  Chromosomal Instability and Tumors Promoted by DNA Hypomethylation , 2003, Science.

[116]  J H Goldie,et al.  A stochastic model for the origin and treatment of tumors containing drug-resistant cells. , 1986, Bulletin of mathematical biology.

[117]  S. Kauffman,et al.  Cancer attractors: a systems view of tumors from a gene network dynamics and developmental perspective. , 2009, Seminars in cell & developmental biology.

[118]  Lynn Doucette-Stamm,et al.  A C . elegans genome-scale microRNA network contains composite feedback motifs with high flux capacity , 2008 .

[119]  J. Troge,et al.  Inferring tumor progression from genomic heterogeneity. , 2010, Genome research.

[120]  Axel Bender,et al.  Degeneracy: a design principle for achieving robustness and evolvability. , 2009, Journal of theoretical biology.

[121]  R. Stephens,et al.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. , 2006, Cancer cell.

[122]  John C Reed,et al.  Heat-shock proteins as regulators of apoptosis , 2003, Oncogene.

[123]  M. Fraga,et al.  Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer , 2005, Nature Genetics.

[124]  A. van Oudenaarden,et al.  MicroRNA-mediated feedback and feedforward loops are recurrent network motifs in mammals. , 2007, Molecular cell.

[125]  J. Stelling,et al.  Robustness of Cellular Functions , 2004, Cell.

[126]  Thomas J. Hardcastle,et al.  Chromosomal instability determines taxane response , 2009, Proceedings of the National Academy of Sciences.

[127]  C. Maley,et al.  Cancer is a disease of clonal evolution within the body1–3. This has profound clinical implications for neoplastic progression, cancer prevention and cancer therapy. Although the idea of cancer as an evolutionary problem , 2006 .

[128]  R. Weinberg,et al.  Species- and cell type-specific requirements for cellular transformation. , 2004, Cancer cell.

[129]  C. Croce,et al.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[130]  Franziska Michor,et al.  Evolution of Resistance to Targeted Anti-Cancer Therapies during Continuous and Pulsed Administration Strategies , 2009, PLoS Comput. Biol..

[131]  Hannah H. Chang,et al.  Transcriptome-wide noise controls lineage choice in mammalian progenitor cells , 2008, Nature.

[132]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[133]  Manel Esteller,et al.  Mutator pathways unleashed by epigenetic silencing in human cancer. , 2007, Mutagenesis.

[134]  A. Knudson Hereditary cancer: Two hits revisited , 2005, Journal of Cancer Research and Clinical Oncology.

[135]  Jarle Breivik,et al.  The evolutionary origin of genetic instability in cancer development. , 2005, Seminars in cancer biology.

[136]  D. Elder,et al.  Familial cutaneous melanoma and two‐mutational‐event modeling , 1993, Cancer.

[137]  S. Kauffman Metabolic stability and epigenesis in randomly constructed genetic nets. , 1969, Journal of theoretical biology.

[138]  Nicholas D. Socci,et al.  Mad2-induced chromosome instability leads to lung tumor relapse after oncogene withdrawal , 2010, Nature.

[139]  Edward R Sumner,et al.  Glutathione and Gts1p drive beneficial variability in the cadmium resistances of individual yeast cells , 2007, Molecular microbiology.

[140]  R. Stephens,et al.  Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. , 2008, Cancer research.

[141]  G. Wagner,et al.  EVOLUTION AND DETECTION OF GENETIC ROBUSTNESS , 2003 .

[142]  S. Sone,et al.  Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases. , 2005, Oncology research.

[143]  Dan S. Tawfik,et al.  Chaperonin overexpression promotes genetic variation and enzyme evolution , 2009, Nature.

[144]  Darryl Shibata,et al.  Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis , 1993, Nature.

[145]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[146]  Martin A Nowak,et al.  Evolutionary dynamics of escape from biomedical intervention , 2003, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[147]  R. Morimoto,et al.  Molecular chaperones and the stress of oncogenesis , 2004, Oncogene.

[148]  M. Greaves,et al.  Phenotypic heterogeneity and cellular origins of T cell malignancies. , 1981, Leukemia research.

[149]  P. Vaupel,et al.  Tumor hypoxia and malignant progression. , 2009, Methods in enzymology.

[150]  T. Richmond,et al.  Crystal structure of the nucleosome core particle at 2.8 Å resolution , 1997, Nature.

[151]  Bryan C. Daniels,et al.  Sloppiness, robustness, and evolvability in systems biology. , 2008, Current opinion in biotechnology.

[152]  S. Lowe,et al.  A microRNA polycistron as a potential human oncogene , 2005, Nature.

[153]  R. Jaenisch,et al.  Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice , 2008, Oncogene.

[154]  A. Knudson,et al.  Two genetic hits (more or less) to cancer , 2001, Nature Reviews Cancer.

[155]  E. Bongcam-Rudloff,et al.  Cell scattering and migration induced by autocrine transforming growth factor alpha in human glioma cells in vitro. , 1997, Cancer research.

[156]  Alexei Kurakin,et al.  Scale-free Flow of Life: On the Biology, Economics, and Physics of the Cell , 2009 .

[157]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[158]  Peter A. Jones,et al.  Epigenetics in cancer. , 2010, Carcinogenesis.

[159]  N. Copeland,et al.  The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer , 1993, Cell.

[160]  Keith L. Ligon,et al.  Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies , 2007, Science.

[161]  Hannah H. Chang,et al.  Non-genetic heterogeneity — a mutation-independent driving force for the somatic evolution of tumours , 2009, Nature Reviews Genetics.

[162]  Allan H Friedman,et al.  Phase II trial of gefitinib in recurrent glioblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[163]  M. Delbrück,et al.  Mutations of Bacteria from Virus Sensitivity to Virus Resistance. , 1943, Genetics.

[164]  Sam W. Lee,et al.  Clonal selection in malignant transformation of human fibroblasts transduced with defined cellular oncogenes. , 2008, Cancer research.

[165]  M. Landthaler,et al.  Overexpression and hyperphosphorylation of retinoblastoma protein in the progression of malignant melanoma , 2005, Modern Pathology.

[166]  Y. Nakamura,et al.  Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.